Table 5.
Open in new tab

Association of Route of Treatment With Flucloxacillin With Median LoS and Rate of Readmission With Cellulitis

nMedian LoS, days (IQR)PReadmission with cellulitis, n (%)P
Total (n = 1525)Oral3610.2 (2.2)25 (7)
IV initially11642.1 (4.0)<.001100 (8).2
Class 1 (n = 858)Oral2180.1 (0.7)12 (6)
IV initially6401.2 (2.9)<.00145 (7).3
Class 1, Lower limb (n = 601)Oral1470.1 (1.1)9 (6)
IV initially4541.5 (3.1)<.00134 (8).4
nMedian LoS, days (IQR)PReadmission with cellulitis, n (%)P
Total (n = 1525)Oral3610.2 (2.2)25 (7)
IV initially11642.1 (4.0)<.001100 (8).2
Class 1 (n = 858)Oral2180.1 (0.7)12 (6)
IV initially6401.2 (2.9)<.00145 (7).3
Class 1, Lower limb (n = 601)Oral1470.1 (1.1)9 (6)
IV initially4541.5 (3.1)<.00134 (8).4

Abbreviation: LoS, length of stay.

Table 5.
Open in new tab

Association of Route of Treatment With Flucloxacillin With Median LoS and Rate of Readmission With Cellulitis

nMedian LoS, days (IQR)PReadmission with cellulitis, n (%)P
Total (n = 1525)Oral3610.2 (2.2)25 (7)
IV initially11642.1 (4.0)<.001100 (8).2
Class 1 (n = 858)Oral2180.1 (0.7)12 (6)
IV initially6401.2 (2.9)<.00145 (7).3
Class 1, Lower limb (n = 601)Oral1470.1 (1.1)9 (6)
IV initially4541.5 (3.1)<.00134 (8).4
nMedian LoS, days (IQR)PReadmission with cellulitis, n (%)P
Total (n = 1525)Oral3610.2 (2.2)25 (7)
IV initially11642.1 (4.0)<.001100 (8).2
Class 1 (n = 858)Oral2180.1 (0.7)12 (6)
IV initially6401.2 (2.9)<.00145 (7).3
Class 1, Lower limb (n = 601)Oral1470.1 (1.1)9 (6)
IV initially4541.5 (3.1)<.00134 (8).4

Abbreviation: LoS, length of stay.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close